REG - SkinBioTherapeutics - Croda Launches Zenakine™ at in-cosmetics Global

SkinbiotherapeuticsAnnouncement

08/04/2025 11:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250408:nRSH1357Ea&default-theme=true

RNS Number : 1357E  SkinBioTherapeutics PLC  08 April 2025

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Croda Launches Zenakine™ at in-cosmetics Global, Amsterdam

·    The first formal, public launch of SkinBiotix, now named Zenakine™,
as Croda's newest active ingredient

·    Launched at in-cosmetics Global, the world's largest cosmetic
ingredients exhibition

·    Described by Croda as a "cutting-edge neuroactive ingredient designed
to counteract the effects of stress on the skin and improve overall wellbeing"

 

8 April 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science company
focused on skin health, announces that its commercial and manufacturing
partner, Croda plc has launched Zenakine™ (previously known as
Skinbiotix™) at in-cosmetics Global 2025, the world's largest cosmetic
ingredients exhibition.

The product has been described as "…a cutting-edge neuroactive ingredient
designed to counteract the effects of stress on the skin and improve overall
wellbeing" and "taking sleep x Emotion x Skin health connection to a new
level."

Information from Croda Beauty's website and media materials:

Zenakine™ is a cutting-edge neuroactive ingredient designed to counteract
the effects of stress on the skin and improve overall wellbeing. It works in
sync with the skin's natural biological rhythms, enhancing melatonin
production to help improve sleep quality, elevating positive emotions and
stimulating skin regeneration. It is the first ingredient with clinical
instrumental measures on sleep quality and duration benefits.

Clinical studies confirmed:

·      An enhanced feeling of happiness in users, showing a 13.5%
increase after one month versus placebo

·      Improved sleep quality, with an 11.3% improvement in just two
weeks

·      A reduction in visible signs of skin fatigue, evidenced by a
lifting effect with a 13.3% increase after one month versus placebo

Comprehensive Benefits for Consumers

Zenakine's wide-ranging benefits have been quantified through comprehensive
trials, demonstrating measurable improvements for both mind and body.
According to Croda Beauty Actives, key advantages include:

·      Improved skin resilience to physical and emotional stressors

·      Smoother skin with reduced lines and signs of tiredness

·      Enhanced emotional balance and sleep quality, promoting a more
rested appearance

·      A sustainability-first approach. Zenakine is crafted through
biotechnology, with 100% natural-origin content (ISO 16128). It is readily
biodegradable and adheres to RSPO and COSMOS standards

Zenakine Benefits for Formulators

For formulators focused on innovation, Zenakine takes a major step by marrying
science with emotion for skin health benefits. The ingredient offers a
clinically backed, multifunctional solution for addressing skin quality while
promoting well-being. It also provides a new avenue for sustainable, clean,
effective cosmetic formulations. Backed by robust data and designed with
sustainability in mind, it is poised to offer a competitive edge to cosmetic
formulators.

Applications listed include:

·    Eye contour care

·    Face / neck skin care

·    Scalp treatments

The ingredient has been launched as five different formulations
(https://www.crodabeauty.com/en-gb/products/product/5852-zenakine#view-formulations)
:

·    Adaptive relaxing face serum

·    Harmonising beauty mist

·    Timeless sleeping mask

·    Bioferment-infused reviving cream

·    Zenakine - clinical studies night cream

For more information on the product, see links below:

Webpage: LINK
(https://www.crodabeauty.com/en-gb/products/product/5852-zenakine)

Press release: LINK
(https://www.globalcosmeticsnews.com/zenakineelevating-sleep-to-timeless-beauty/)

Commercial agreement

SkinBioTherapeutics finalised commercial terms with Croda following successful
additional studies of its skin lysate. The terms include tiered royalties
based on global sales revenues on any licensed products derived from the
partnership.

Under the terms of the agreement, all details about formulation, functionality
and Croda's financial expectations remain confidential due to the
competitiveness of the cosmetics market. Any royalty revenues arising from
future sales will be reported to the market at the appropriate time.

 

Stuart Ashman, CEO of SkinBioTherapeutics, said:

"The international launch of Zenakine™ by Croda has been a long anticipated
event for the SkinBioTherapeutics team and our investors. We could not be more
delighted with the initial launch impact and the excitement of the Croda team
to be able to talk about Zenakine™ to the global industry at long last.

"Croda is reporting that this is the first scientifically proven active
ingredient for anti-ageing application, and together with the formulation
options in their marketing literature, tells a compelling story to the
cosmetics industry. We will be monitoring initial industry interest on the
ground for this first range of applications."

-Ends-

 

Images from the in-cosmetics global conference, showing the Croda stand and
Zenakine™ exhibition stands.

 

 Image of Croda stand at    Image of Zenakine™             Image of Zenakine™

in-cosmetics global 2025
study results on Croda stand
details on Croda stand

 

SkinBiotix launch presentation webinar

The management team will hold an Investor Meet Company presentation at 11am
BST on 16 April 2025. At this presentation, the team will update
shareholders on both the HY results and the launch.

The presentation will be open to all existing and potential
SkinBioTherapeutics shareholders. Questions can be submitted pre-event via
the Investor Meet Company dashboard
(https://www.investormeetcompany.com/companies/skinbiotherapeutics-plc)  up
until 15 April 2025, 09.00am BST, or at any time during the live
presentation. Investors who already follow SkinBioTherapeutics plc on
the Investor Meet Company platform will automatically be invited.

Investors who already follow SkinBioTherapeutics on the Investor Meet
Company platform will automatically be invited. Investors can sign up
to Investor Meet Company for free HERE
(https://www.investormeetcompany.com/) .

 

For more information please contact:

 

 SkinBioTherapeutics plc                            +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

 Manprit Randhawa, CFO

 Cavendish Capital Markets Limited                  +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson (Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis, Tamar Cranford-Smith (Sales)

 Vigo Consulting (financial press)                  +44 (0) 20 7390 0230

 Rozi Morris                                        SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare (SkinBiotix)
and food supplements to modulate the immune system by harnessing the gut-skin
axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and
the Group's first in-house product, AxisBiotix-Ps™, is a food supplement to
address the symptoms of mild to moderate psoriasis.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skin care and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGCGDSIUGDGUI